Description
Matrix GLa protein inhibits vascular calcification in a vitamin K-dependent manner. Serum levels of this peptide may be used as a biomarker for renal failure, diabetes, and cardiovascular events.
| Product Unit Size | Cost | Quantity | Stock |
|---|
Matrix GLa protein inhibits vascular calcification in a vitamin K-dependent manner. Serum levels of this peptide may be used as a biomarker for renal failure, diabetes, and cardiovascular events.
| Purity | ≥95% |
|---|---|
| Formula | C18H25N5O5S |
| Formula Wt. | 423.4 |
| Synonym | MGP-pNa |
| Solubility | Soluble in water. |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
McCarty MF, DiNicolantonio JJ. The molecular biology and pathophysiology of vascular calcification. Postgrad Med. 2014 Mar;126(2):54-64. PMID: 24685968.
Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med. 2013 Apr;19(4):217-26. PMID: 23375872.
Fluoroquinolone; bacterial DNA gyrase inhibitor...
Polyene macrolide, induces pore formation in fu...
For use in amino acid analysis.
Rapamycin analog
VEGFR, PDGFR, c-Kit inhibitor.
Mycotoxin produced by Penicillum and Aspergillu...
Glycosaminoglycan
VEGFR1/2/3, TIE2, PDGFRβ, FGFR1, c-Kit, RET, B...
Sulfonamide; dihydropteroate synthase inhibitor...
Endogenous neuropeptide hormone, involved in so...
Selective and reversible JAK inhibitor.
5-α-Reductase inhibitor.
Thienopyridine; P2Y12 antagonist.
Antioxidant.
Cannabinoid receptor 2 selective agonist.
BRD2/4/9 and CECR2 inhibitor.
AChE inhibitor.
Fluoroquinolone; bacterial DNA gyrase inhibitor...
Fibrate; PPARα agonist, enoyl-CoA reductase in...